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Drug screening: zebraﬁsh as a tool
for studying epileptic-related chemical
compounds
Dear Editor,
Here we report ﬁndings of zebraﬁsh behavior and develop-
ment during drug screening. In developing zebraﬁsh
embryos, epileptic seizure-like locomotor defects can be
induced by brief treatment with GABAA receptor antagonist
pentylenetetrazole (PTZ). Using a trajectory video tracking
system, we recorded zebraﬁsh movements and constituted
convulsant-like locomotor behaviors after treatment with
PTZ. This led to the development of the ﬁrst 3-D trace map of
zebraﬁsh locomotor behaviors in response to drug treat-
ment. In addition, we examined the dose-dependent rescues
of the locomotor defects in PTZ-treated animals after treat-
ment with anti-epileptic drugs, such as valproate (VPA). We
also examined the effects of drug treatment on animal
development, such as hatching and mortality. Together, this
research sheds new light for the development of new
strategies for high-throughput drug screens using zebraﬁsh
models.
Zebraﬁsh maintain a great evolutionary proximity to
mammalian species, and have been used as a model
organism for studying vertebrate developmental biology,
physiology, and human disease (Paw and Zon, 2000; Chen
and Ekker, 2004). Complementing the existing laboratory
animals, zebraﬁsh also created a niche in the ﬁeld of drug
discovery (Kaufman et al., 2009; Laggner et al., 2011; Gut
et al., 2013). Recent studies suggest that zebraﬁsh is suit-
able for screening compounds that target the molecular and
cellular pathways involved in human diseases, such as
cancer, heart failure, metabolic dysfunction and neural
degenerative disorders (Owens et al., 2008; Kitambi et al.,
2009; Baraban et al., 2013). A large number of synthetic and
natural compounds have been identiﬁed, which include
those that facilitate the survival of dopaminergic cells, protect
auditory hair cells, enhance angiogenesis in regenerating
nerve tissues, or increase neural regeneration by promoting
the activity of radial glial progenitor cells. Molecular and
cellular analyses of the products from the previous screens
revealed that some of the newly identiﬁed compounds hold
the potential for therapeutic treatment of neurological
disorders, such as epilepsy, ataxia, sensorineual deafness,
or tubulopathy. Also, through the screens, a large number of
compounds that target the cascade of neural signaling
transduction have been identiﬁed, such as those that mod-
ulate the activity of Shh, IGF or TGFβ pathways (Chen et al.,
2009; Yang et al., 2013).
Epilepsy is a central nervous system disorder resulting
from excessive and hyper-synchronous electrical dis-
charges of the nerve cells (Hortopan et al., 2010). In zeb-
raﬁsh, epileptic seizure-like behaviors can be induced by
treatment with GABAA receptor antagonists, such as PTZ
(Baraban et al., 2007; Afrikanova et al., 2013). While PTZ
efﬁciently induces epileptic seizure-like behaviors, the
characteristics of such behaviors and the effects of PTZ
treatment in animal development have not been thoroughly
examined. We characterized the zebraﬁsh locomotor
behaviors in response to epilepsy-speciﬁc drug treatment
using a trajectory video tracking system based on a frame
differential method (Sonka et al., 1998). In the absence of
external stimuli such as gentle touches, disturb of swim-
ming water, or tap of the container, the zebraﬁsh embryos
display very little spontaneous movements. At 7 days post-
fertilization (dpf), for example, during a 30-min recording
period, at most times the embryos were still and positioned
toward the wall of the container and stayed at the bottom of
the container (Fig. 1A, Row 1; Fig. 1B). The embryos dis-
played only a few instances of spontaneous movement
(Fig. 1C), which resulted in less than 10 cm of total
swimming distance (Fig. 1C).
Treatment with PTZ (20 mmol/L; treatment time: 5 min)
induced epileptic seizure-like locomotor behaviors, which
include ictal, twitching, loss of posture, spiraling, and unco-
ordinated jerky movement. The embryos constantly moved,
either along the wall of the container or crossed the middle of
the container (Fig. 1A, Row 2). They were found in the bot-
tom of the container as well as in the middle- and upper-part
of the container (Fig. 1B). During a 30-min recording period,
on average each embryo displayed 832.7 ± 339.7 instances
of hyperactive movement, which resulted in
931.4 ± 509.4 cm of total swimming distance (Fig. 1C).
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Treatment with VPA led to dose-dependent rescues of the
hyperactive locomotor behaviors caused by PTZ. During the
30-min recording period, in response to a low concentration
of VPA (e.g., 0.25 mmol/L), no signiﬁcant changes in swim-
ming patterns or total swimming distances were detected
(Fig. 1A, Row 3; Fig. 1B; Fig. 1C). Along with the increase of
VPA concentrations (0.50 mmol/L, 0.75 mmol/L), the loco-
motor defects caused by PTZ gradually diminished (Fig. 1A,
Rows 4, 5; Fig. 1B; Fig. 1C). When the concentration of VPA
increased to 1.0 mmol/L, the locomotor defects caused by
PTZ were completely rescued. For example, at most times



























































































































































































Figure 1. Locomotor behaviors of control and drug-treated zebraﬁsh embryos (7 dpf). (A) Representative locomotor traces (red
lines) of embryosduringa30-min recordingperiod. Theembryoswere kept in individualwells in the48-well plate, oneembryoperwell.Row
1, control embryos maintained in system-water; Row 2, PTZ- treated (20 mmol/L; treatment duration, 5 min) embryos; Row 3–6, PTZ
(20mmol/L) andVPA (in different concentrations) treatedembryos.Note the increase in locomotor behaviors in response toPTZ treatment.
Theapplication ofVPA resulted indose-dependent rescues of the locomotor defects inPTZ-treatedembryos. (B)Representative 3D traces
(red lines) of locomotorbehaviors recorded fromazebraﬁshembryobeforeandafter drug treatment (recordingperiod, 30min). Theembryo
was kept in a well in the 48-well plate. In the control medium, the embryo spent most of the times at the bottom of the container and only
displayed a few spontaneous movements. In response to PTZ treatment, the embryo became hyperactive, and swam in both the top and
bottom half of the container. The application of VPA (0.25, 0.5, 0.75, and 1.0 mmol/L) produced dose-dependent rescues of the locomotor
defects caused by PTZ. (C) Locomotor behaviors in control and drug treated embryos. Left: the number of spontaneous movement in
control, PTZ, and PTZ + VPA treated embryos. Right: total swimming distances in control and drug-treated embryos. Data represents the
mean ± SEM, n = 30; *P < 0.05; **P < 0.01.
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Row 6; Fig. 1B), and the number of spontaneous locomotor
movement and the total swimming distance were reduced to
levels similar to control embryos (Fig. 1C).
To further investigate the effect of PTZ treatment on
zebraﬁsh development, we developed an assay based on
membrane deformation in response to micropipette aspira-
tion that is suitable for measuring the stiffness of the chorion
membrane that surrounds the embryo before hatching
(Fig. 2A). In control embryos, a linear pressure-length curve
(P-L curve; aspirated pressure-membrane length) of chorion
membrane can be recorded (Fig. 2B). Using this assay, we
measured the shear modulus of the chorion membrane in
response to PTZ treatment. The experiments were con-
ducted in developing embryos treated with different con-
centrations of PTZ (10, 20, 30 and 40 mmol/L) or different
treatment durations (between 1 and 7 h post-fertilization;
hpf). Chorion membrane shear forces were measured at
24 hpf.
Treatment with PTZ increased the stiffness of the chorion
membrane. In control embryos, the maximum shear force
(membrane ﬂexibility) was obtained approximately 240 ms
after the onset of aspiration. The times that required to reach
the maximum shear forces decreased to 177 ms and
149 ms, respectively, when PTZ was applied at 20 mmol/L
and 40 mmol/L (Fig. 2C). In all cases (treated with different
concentrations or different durations), the stiffness of the
chorion membrane increased as compared to that recorded
from control embryos (Fig. 2D and 2E). No obvious differ-
ences in membrane stiffness were observed when the
embryos were treated using different PTZ concentrations
(between 10 mmol/L and 40 mmol/L) or with different treat-
ment durations (from 1 to 7 hpf) (Fig. 2D and 2E).
The increase of chorion stiffness due to PTZ treatment
resulted in signiﬁcant delays in hatching, particularly when
PTZ was applied at high concentrations. In control animals
kept in fresh system-water, at 3 days dpf, 78.6% ± 4.8% of
the embryos hatched out of the chorion. By 5 dpf,
87.1% ± 4.9% of the embryos hatched (Fig. 2F). In response
to PTZ treatment (20 mmol/L, 3 h of treatment between 3
and 6 hpf), no signiﬁcant differences were observed in the
hatching rate between the control and drug-treated embryos.
When PTZ concentration was increased to 40 mmol/L, the
hatching rate was decreased. For example, at 3 dpf only
5.0% ± 4.9% of the embryos hatched. When examined at 5
dpf, the hatching rate increased to 68.3% ± 4.8% (Fig. 2F),
but still signiﬁcantly lower than the hatching rate in control
animals (P < 0.05). In response to PTZ treatment, the
mortality of the embryos increased. In the control group,
approximately 10%–13% of the embryos died when coun-
ted at 3 and 5 dpf (Fig. 2G). These included unfertilized
eggs and embryos that had developmental defects. After
PTZ treatment (20 mmol/L), the mortality rate increased
to 20.8% ± 4.8% and 22% ± 5.0%, respectively, when
examined at 3 and 5 dpf (Fig. 2G). Along with the increase
of PTZ concentration (to 40 mmol/L), the mortality was
further increased, i.e., to 30.1% ± 4.8% and 31.6% ± 6.7%
when counted at 3 and 5 dpf (Fig. 2G). The embryos that
survived PTZ treatment showed no obvious morphologic
or locomotor defects in comparison to untreated control
embryos.
In summary, zebraﬁsh embryos display sophisticate
locomotor behaviors in response to ambient stimuli and they
are suitable for drug screens. Previously, the role of PTZ
treatment on zebraﬁsh neural activities (in the optic-tectum)
and locomotor behaviors has been examined (Afrikanova
et al., 2013). However, the characteristics of PTZ-induced
locomotor defects, such as the frequency of convulsant-like
movements, swimming patterns, dose-dependent rescues
after VPA treatment, and the effects of PTZ treatment on
animal development, remain to be determined. While this
study did not investigate the mechanisms of epilepsy, it
provided methods for studying the locomotor defects and
development of zebraﬁsh models with epilepsy. The loco-
motor trace maps generated by the trajectory video tracking
system provide the ﬁrst multi-dimensional (2D or 3D) views
of the zebraﬁsh locomotor behaviors in response to drug
treatment. Instead of showing the representative locomotor
characteristics collected at speciﬁc time points after drug
treatment, the trace maps provide a tool for in vivo studies of
drug effects on animal behaviors during the entire treatment
period. It paves the way for functional analysis of the drugs
on neural activity.
The newly developed biophysical assay provides a tool
for monitoring the toxicity levels of drug treatment on animal
development. Speciﬁcally, it provides data that correlate the
increase of chorion stiffness, delay of hatching, and the
increase of mortality in response to drug treatment. Noted
that when treated with different concentrations of PTZ or
when treated with different time duration, no detectable dif-
ferences in chorion membrane shear force were observed
using our assays. Treatment with 20 mmol/L of PTZ did not
signiﬁcant affect the hatching, but increased the rate of
mortality. With the increase of PTZ contraction (40 mmol/L),
the hatching rate was decreased and the mortality was fur-
ther increased. The delay of hatching may be attributed to
the increase of animal mortality, i.e., due to decreased
amount of oxygen or delay of food intake. It is possible that
before hatching (approximately 3 dpf) the egg chorion acts
like an effective barrier that protects the embryos from
exposure to chemicals. From this point of view, it is con-
ceivable to propose that for future drug screens, especially
when the screens are conducted in zebraﬁsh embryos dur-
ing early developmental stages, de-chorination of the
embryos may improve the result of the screens.
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Figure 2. Effects of PTZ treatment on zebraﬁsh develop-
ment. (A) Diagrams that show the experimental set up for
measuring the shear force of chorion membrane. From left to right:
the pipette approached the embryo, attached to the chorion
membrane, appliedaspirationand recordedshear forces,withdrew
from the chorion membrane. (B) Traces of theoretical and exper-
imental P-L curves obtained from a 24-hpf control embryo. In both
cases, linearP-L relationshipswere obtained. (C)Tracesof chorion
membrane shear forces in control and PTZ-treated embryos. Note
the increase of membrane stiffness (decreases in time required to
reach the maximum shear force) in response to PTZ treatment.
(D) Chorion membrane shear forces recorded from zebraﬁsh
embryos (24 hpf) treated with different concentrations of PTZ (10,
20, 30 and 40 mmol/L). (E) Chorion membrane shear forces
recorded from embryos (24 hpf) treated with 20 mmol/L PTZ for
different durations (1, 3, 5 and 7 h). (F) Hatching rates at 3 and 5dpf
in control (grey bars) and PTZ-treated embryos (black and white
bars). When PTZ was applied at 20 mmol/L (black bars), no
signiﬁcant decreases in the hatching rates were detected. When
PTZ was applied at 40 mmol/L (white bars), the hatching rate was
decreased in both 3 and 5 dpf embryos. (G) Mortality rates
determined at 3 and 5 dpf in control (grey bars) and PTZ-treated
embryos (black and white bars). In response to PTZ treatment
(20 mmol/L, black bars; 40 mmol/L, white bars), signiﬁcant
increases in the death of the embryos were observed at both 3
and 5 dpf. Data represents the mean ± SEM, n = 30; *P < 0.05;
**P < 0.01, ns: not signiﬁcant.
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